Dr. Amit Oza is Head of the Division of Medical Oncology & Hematology, and Medical Director of the Cancer Clinical Research Unit at Princess Margaret (PM) Cancer Centre. He is also co-Director of the Drug Development Program at PM Cancer Centre, Scientist at the Ontario Cancer Institute, and Professor of Medicine at University of Toronto. Dr. Oza has been PI and co-investigator in >100 phase I, II and III trials for gynecological cancer and advanced colorectal malignancies. He is the past co-chair of the National Cancer Institute Gynecologic Cancer Steering Committee, and Executive Member of the international Gynecologic Cancer InterGroup. Under his direction, the gynecology group is one of the largest ovarian cancer (OC) clinical trials groups consistently accruing >30% of all patients seen onto clinical trials (>120/yr) at PM Cancer Centre. Under his direction the group has participated or led seminal studies in gynecologic cancers that have led to the approval or use of targeted agents such as PARP inhibitors (olaparib, niraparib) and anti-angiogenic agents (bevacizumab) internationally. Since 2011, he has obtained >$36.9M in peer-reviewed funding and has published >180 articles (all types) in journals, including the New England Journal of Medicine (IF=53); Lancet Oncology (IF=16), and the Journal of Clinical Oncology (IF=16.4).
Amit M Oza
Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer.
Clin Cancer Res. 2015 Jan 14;
Performance Characteristics of a Brief Family History Questionnaire to Screen for Lynch Syndrome in Women with Newly Diagnosed Endometrial Cancer.
Gynecol Oncol. 2014 Dec 18;
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Lancet Oncol. 2014 Dec 3;
Eur J Cancer. 2014 Dec;50(18):3271-2
Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials.
Cancer. 2014 Oct 21;
Estimation of expectedness: Predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer.
Cancer. 2014 Oct 2;
Gynecol Oncol. 2014 Aug 27;
Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing.
Cancer. 2014 Jul 31;
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
Lancet Oncol. 2014 Jul;15(8):799-808
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Co-director, Robert and Maggie Bras and Family Drug Development Program
Professor, Department of Medicine, University of Toronto
Head, Department of Medical Oncology & Hematology